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Abstract 
Objective: To compare the efficacy of crystalloid versus colloid solutions, specifically normal 
saline versus albumin, in decreasing mortality among patients with septic shock requiring 
resuscitation fluids in the intensive care unit (ICU) setting. Design: Systematic literature review. 
Methods: Research was conducted in PubMed and UpToDate, utilizing the search terms 
sepsis, septic shock, fluid resuscitation, colloids and crystalloids. Specifically, in PubMed, the 
following limits and terms were used: randomized control trial, human subjects, English, and 
within the last 7 years. Results: The Annane et al study found no significant difference in colloid 
fluid resuscitation versus crystalloid fluid resuscitation in the decreasing 28-day mortality in 
hypovolemic shock patients specifically in the ICU setting. The Finfer et al study found no 
significant difference between albumin and normal saline when assessing 28-day mortality and 
morbidity for patients in the ICU with severe sepsis. The Caironi et al study found no significant 
difference in albumin and crystalloids co-administration compared to crystalloids alone in 28-day 
mortality and morbidity outcomes for those with septic shock admitted to the ICU. Conclusion: 
The choice of fluid in aggressive resuscitation has no significant effect on patient mortality in 
those with septic shock in the intensive care unit (ICU).  
 
Introduction 
Sepsis is defined as a severe infection that has spread from one site, into the systemic 
circulation and has the potential become life threatening in the event of septic shock. It is 
estimated that 1 out of every 3 patients that die while in the hospital have sepsis ¹. A 
complication of sepsis occurs when chemicals, commonly known as bacterial exotoxins, are 
released from live bacteria into the bloodstream. The body’s response to these exotoxins is a 
heightened inflammatory response, which is meant to fight the infection, but instead can lead to 
vasodilation and subsequent distributive shock². The hallmarks of septic shock are hypotension, 
tachypnea, oliguria, mental status changes, metabolic acidosis and elevated lactate levels due 
to increased cell damage². Typically, the offending organism or source of infection is unknown 
at the time of arrival to the emergency department (ED) with suspected septic shock². Sepsis 
and shock are clinical diagnoses, therefore there is no diagnostic test to be performed on 
arrival³. The cornerstone of emergent intervention is aimed at mitigating hypovolemia by 
maintaining perfusion to all organs with aggressive fluid resuscitation and beginning empiric 
antibiotic therapy³. The initial assessment of a suspected shock patient who presents to the ED 
is to protect the airway if indicated, assess oxygen saturation, draw blood cultures, and 
establish IV access to rapidly administer antibiotics and fluids³. Additionally, while the patient is 
being stabilized, a tool known as “systemic inflammatory response syndrome (SIRS) criteria”, 
outlined in Table 1, is used to assess if the patient meets the criterion for a sepsis diagnosis, 
which can aid in determining treatment protocols⁴. If the patient meets SIRS criteria, they are 
typically admitted to the intensive care unit (ICU) for continuous fluid maintenance and 
observation with serial hematologic lab studies, chemistries and ABG’s³. While in the ICU, the 
patient’s work up continues to determine the source of infection in order to tailor antibiotic 
therapy and determine if further intervention such as intubation, dialysis, or surgery is 
necessary.   
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In the current literature, there continues to be an ongoing debate about the optimal choice of 
fluid for intravenous resuscitation in those diagnosed with sepsis or septic shock. When 
considering the proper resuscitation fluid, determining the extent of fluid loss and presence of 
electrolyte abnormalities is a key prognostic factor and must be addressed in this patient 
population³. Two types of fluids most commonly used in resuscitation of sepsis or shock patients 
are crystalloid and colloid containing solutions⁵. An example of a crystalloid solution is isotonic 
(normal) saline, which by definition is meant to mimic the normal serum sodium concentration 
and thus, help keep fluid in the intravascular space⁵. Colloid fluids, in comparison, are solutions 
like albumin, which mimic proteins made by the liver and aid in holding fluid in the intravascular 
space via increasing the serum osmolality⁵. When a patient presents with marked hypotension, 
both crystalloid and colloid solutions are options to use when attempting to replace lost 
extracellular fluid⁵. Typically, the fluid most commonly used is normal saline since it is plentiful, 
inexpensive, and leads to good outcomes in patients with severe volume depletion not due to 
bleeding⁵. Despite these benefits, 1.5 to 3 times more saline, as compared to a colloid solution, 
is needed in order to expand the plasma volume when loss is due to third spacing⁵. This is 
disadvantageous because it increases the potential for fluid overload, which in turn could 
negatively impact patient outcomes⁵. Therefore, some clinicians prefer the use of albumin over 
normal saline in patients with sepsis or septic shock because of its rapid plasma volume 
expansion, its low risk for dilutional hypoalbuminemia, and its ability to rapidly stabilize patients 
without increasing the risk of pulmonary edema⁵. In this paper, we will examine mortality rate of 
sepsis and septic shock patients who receive crystalloid fluid resuscitation versus those patients 
who receive colloid fluid resuscitation. Our research goal is to determine the best choice for fluid 
resuscitation that will result in good patient outcomes and overall decreased patient mortality in 
the setting of sepsis and septic shock in the ICU. 
 
Table 1.  Systemic inflammatory response syndrome criteria used in diagnosis of shock⁴ 
Systemic Inflammatory Response Syndrome (SIRS) Criteria 
2 or more of the following variables: 
Fever more than 38°C (100.4°F) or less than 36°C (98.6°F) 
Heart rate of more than 90 beats per minute 
Respiratory rate more than 20 breaths per minute or arterial carbon dioxide tension (PaCO2) of less than 32 mm Hg 
Abnormal white blood count (>12,000/mL or <4,000/mL or >10% immature (bands) forms) 
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Methods  
A PubMed search was conducted in 
September 2018 using the terms sepsis, 
septic shock, fluid resuscitation, colloids 
and crystalloids. This search yielded 20 
studies with pertinent subject matter to our 
clinical question. To further narrow our 
PubMed finds, we limited our search to 
include only randomized control trials with 
human subjects, published in English within 
the last 7 years. In addition to PubMed, 5 
additional resources were gathered by 
assessing primary research articles cited by 
UptoDate in the “related articles” section of 
texts discussing choice of IV fluid 
resuscitation in shock patients and defining 
sepsis, severe sepsis and septic shock and 
the management thereof. No duplicate 
articles were discovered when combining 
the articles from our PubMed and UptoDate 
searches. In total 22 articles were screened 
and 18 articles that were meta-analyses, 
systematic reviews, and secondary subgroup analyses were excluded. In addition, articles that 
did not reflect our clinical question were excluded. Such articles did not fit our research question 
because of differing endpoints, various types of solutions, conduction of studies in non-ICU 
settings and pilot studies that were analyzing the function and potential success of a larger, 
future study. Lastly one full text article was excluded since it was published more than 7 years 
ago resulting in 3 sufficient articles for assessing the fluid choice in the setting of aggressive 
resuscitation in septic shock patients. 
 
Results 
Study 1: Effects of Fluid Resuscitation with colloids vs crystalloids on mortality in critically ill 
patients presenting with hypovolemic shock⁶ 
Objective: To compare colloid fluid resuscitation versus crystalloid fluid resuscitation in altering 
28-day mortality in hypovolemic shock patients specifically in the ICU setting. 
 
Study Design 
This study is a multicenter, randomized control trial conducted in ICU’s based in France, 
Belgium, North Africa and Canada. The study was conducted over 9 years from February 2003 
to August 2012. 2857 patients were divided into 2 different treatment groups, 1414 patients 
receiving colloid fluids and 1443 patients receiving crystalloid fluids, via blinded computer-
generated permuted block randomization algorithm. Consent was obtained from participants or 
legally authorized surrogates. Inclusion and exclusion criteria are represented in Table 2. The 
study defines acceptable crystalloid fluids as isotonic or hypertonic saline or lactated ringers and 
Figure 1. PRISMA diagram in this systematic review. 
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the acceptable colloid solutions include gelatins, dextrans, hydroxyethyl starches, or 4% or 20% 
of albumin. Patients were stratified according to admission diagnoses that defined the cause of 
their states of shock: trauma, sepsis or other. The time and amount of therapy was up to the 
discretion of the investigator under the condition that the daily dose of hydroxyethyl starch 
(colloid solution) did not exceed 30 mL/kg and the investigators strictly followed any local 
regulatory agency recommendations that governed use of resuscitative fluids. The trial was 
discontinued when there was enough information to make a conclusion. This primary endpoint 
was said to be achieved when there was a 5% difference in the number of deaths between the 
two treatment groups at 28 days. Other outcomes being studied were mortality at 90 days, days 
without renal replacement, presence of organ failure (using Sequential Organ Failure 
Assessment (SOFA) scores), ICU and hospital-free days, days alive without mechanical 
ventilation, and days without use of vasopressors. 
 
Table 2.  Inclusion and exclusion criteria for Study 1. 
Inclusion Criteria Exclusion Criteria  
1. Admission to ICU 1. Advanced chronic liver disease  
2. No prior fluid resuscitation while in ICU  2. Anesthesia related hypotension  
3. Hypotension: < 90/<60 with orthostatic hypotension (20 mmHg change) 
or delta pressure of 13% 
3. Acute anaphylactic reaction 
   
4. Evidence of low cardiac index & low filling pressures 4. Pregnancy 
5. Signs tissue hypoperfusion: 5. Inherited coagulopathy 
- GCS < 12 6. Burn > 20% BSA 
- Mottled skin 7. Allergy to study drug 
- Capillary refill ≥ 3 sec 8. Refused consent 
- Arterial lactate levels > 2 mmol/L 9. Dehydrated 
- BUN > 56 mg/dL 10. Brain dead  
- Urinary output < 25 mL/hr 11. Organ donor 
- Fractional excretion of sodium < 1% 12. Renal failure 
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Study Results 
When the primary endpoint of mortality in 28 days was achieved, there were 359 deaths in the 
colloids group and 390 deaths in the crystalloid group (RR: 0.96, 95% confidence interval (CI) 
0.88 to 1.04; p = 0.26). A value of less than 0.05 is considered statistically significant. In the first 
7 days of treatment in the ICU, the median amount of colloid fluid used per patient was 2000 mL 
[IQR: 1000-3502 mL] and in the crystalloid group, a median of 3000 mL [IQR: 500-5200 mL]. 
 
Figure 2.  Incidence of death within the first 28 days after randomization  
 
 
Study Critique  
The study is large and based on primary data which, in itself a source of strength. The reliability 
of data and conduction of the study is strong as evidenced by the auditing of each successive 
part of the trial. Inspection of the validity of informed consent, compliance to good clinical 
practice, validity of patient chart information, compliance to protocol, and accuracy of reporting 
adverse events at random times throughout the study, produced reliable data. Conduction of 
this study was overseen and funded by the French Ministry of Health, which is yet another 
positive aspect of this study as that entity is an unbiased governing party. Despite two conflicts 
of interest, the relationship and exchanges were explicitly stated in the study. The random 
allocation of patients by a blinded permuted block structure is the gold standard in quality 
randomized clinical trials and speaks to the validity of the study. However, the blinding of the 
investigators administering fluids was only hidden until the fluid bag was opened. This can be 
seen as a potential flaw in study design by creating performance bias but was deemed 
inevitable by the researchers. To offset the lack of complete blinding, investigators who were 
fully blinded throughout the duration of the trial were the individuals collecting and interpreting 
data. One finding that weakens the study is the administration of supplemental albumin alone to 
237 patients in the crystalloid group. Although this was not deemed an exclusionary criterion in 
this study, future studies may add this criterion since it could have skewed the data collected 
and the conclusions made in this paper. 
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Study 2: Impact of albumin compared to saline on organ function and mortality of patients with 
severe sepsis⁷ 
Objective: To determine which fluid, albumin or normal saline, is more effective for acute 
resuscitation by assessing 28-day mortality and morbidity in patients in the ICU with severe 
sepsis. 
Study Design 
This is a subgroup analysis study used to further the research done by a larger randomized 
control trial conducted in the intensive care unit (ICU) of 16 hospitals throughout Australia and 
New Zealand between November 2001 and June 2003. The initial goal of the study was to 
determine which fluid, albumin or normal saline, was more effective for resuscitation in those 
presenting with severe sepsis. Much like the initial study, this study took place in the ICU of 
multiple hospitals throughout Australia and New Zealand and looked at the effectiveness of fluid 
resuscitation in those with sepsis at baseline. The study design used in this subgroup trial was a 
double-blinded, randomized control trial that involved 1218 patients, all of which presented 
initially with severe sepsis. The source of sepsis was derived from the ICU admission diagnosis. 
When the admission diagnosis did not specify the source of sepsis, it was determined by 
retrospective analysis of medical records. Adult patients were randomly assigned to 4% albumin 
or 0.9% sodium chloride for all fluid resuscitation needs while being treated in the ICU for 
severe sepsis. After randomization was completed, 603 patients had been assigned 4% albumin 
and 615 patients that had been assigned 0.9% normal saline as the primary method of 
resuscitation while in the ICU. Fluid therapy was continued in the ICU until death, discharge, or 
28 days after randomization, whichever occurred first. Inclusion and exclusion criteria for the 
selection of participants are presented in table 3. The primary outcome followed throughout the 
study was mortality within the first 28 days of randomization. Other outcomes being followed 
included, length of ICU stay, length of hospital stay, duration of mechanical ventilation, and 
duration of renal replacement therapy.   
 
Table 3.  Inclusion and exclusion criteria for Study 2. 
Inclusion Criteria Exclusion Criteria  
Patients in the ICU with sepsis (two of the following)  Admitted to the ICU status post 
- a core temperature ≥ 38° C o ≤ 36° C - Cardiac surgery 
- a heart rate ≥ 90 beats/min - Liver transplant 
- a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of 
mechanical ventilation for an acute process 
- Severe burns  
- a white blood cell count ≥ 12000/ml or ≤ 4000/ml or immature 
neutrophils > 10% 
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Study Results  
Of 1218 patients enrolled, 185 assigned to albumin died, and 217 assigned to normal saline 
died (odds ratio 0.87; 95% confidence interval 0.74–1.02; p = 0.09). A value of less than 0.05 is 
considered statistically significant. Of these, 121 patients in the albumin group and 138 patients 
in the normal saline group died within 7 days of administration. 151 in the albumin group and 
177 in the saline group died while in the ICU. Of those that died elsewhere in the hospital, 34 
patients were assigned albumin and 40 were assigned normal saline. Furthermore, during the 
28-day follow-up period, no patients who presented with severe sepsis died following hospital 
discharge. 
 
Table 4. Primary and Secondary Outcomes for those with sepsis.  
 
  
Study Critique  
In this study, data was derived from a subgroup of a large blinded, randomized clinical trial 
(RCT) which is a strength because RCT is the gold standard for evidence-based medicine. A 
weakness of this study was it was a subgroup of a larger trial; therefore, the sample size was 
not predetermined. Additionally, the trial was not primarily designed to examine the relative 
benefits of albumin and normal saline in severe sepsis, which in turn might be considered a 
weakness. Moreover, in the study, researchers were unable to collect detailed microbiological or 
associated treatment data for each patient, leading to a potential imbalance in associated 
treatments. The imbalance may favor those assigned to albumin and in turn could have 
influenced the results. Additionally, another weakness of the study was that not all patients were 
included in the multivariate analysis because some were missing primary evaluation data. In the 
study, fluid resuscitation was not delayed to collect non-routine samples for laboratory data nor 
was it delayed to measure parameters such as the CVP, which were used for assessment. By 
not including all participants involved in the trial, that could have introduced selection bias or 
further decreased the sample size, leading to type two error. Finally, another weakness to the 
study was that Sequential Organ Failure Assessment (SOFA) scores were not collected after 
patients were discharged from the ICU, which in turn weakens the inferences drawn from this 
data. 
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Study 3: Albumin Replacement in Patients with Severe Sepsis or Septic Shock⁸ 
Objective: To determine if albumin and crystalloid fluid compared to crystalloid fluid alone 
results in better 28-day mortality and morbidity outcomes for those with septic shock admitted to 
the ICU.   
 
Study Design 
This study was a randomized control trial initiated in 100 intensive care units (ICU) in Italy, from 
August 2008 to February 2012. The study contained 1818 patients who were randomly 
assigned to either 20% albumin and 0.9 % normal saline or 0.9% normal saline alone for fluid 
replacement while in the ICU. Inclusion and exclusion criteria used in the selection of 
participants are presented in table 5. Randomization was stratified according to the participating 
ICU and the interval of time between which the patient met the clinical criteria for severe sepsis 
and randomization. A total of 8 patients were excluded from the analysis. 2 patients in the 
albumin group were excluded due to withdrawal of consent. 5 patients in the albumin group 
were excluded due to a randomization error. 1 patient in the crystalloid group was excluded due 
to a randomization error. Length of fluid therapy in the ICU was based on early goal directed 
therapy and was measured from the time of randomization until 28 days, death, or discharge, 
whichever came first. Directly after randomization was completed, patients in the albumin group 
received 300 mL of 20% albumin solution, whereas the crystalloid group received nothing. 
Furthermore, from day 1 to day 28 or prior to discharge, whichever came first, 20% albumin was 
administered on a daily basis, to maintain a serum albumin level of 30 g per liter or more. 
Crystalloids were only administered whenever it was clinically indicated by the attending 
physician managing the patient. Moreover, in this study there were two outcomes that were 
being measured. The first outcome, the primary outcome, was death from all-cause mortality at 
28 days after randomization. The second, the secondary outcome, was death from all-cause 
mortality at 90 days after randomization. Other outcomes being followed included number of 
patients with organ dysfunction, the degree of dysfunction, and the length of stay in the ICU and 
hospital. In the study, the severity of systemic illness was assessed using the Simplified Acute 
Physiology Score, ranging from 0, meaning low severity, to 163 indicating the highest level of 
severity. Finally, organ function was assessed daily using the Sequential Organ Failure 
Assessment (SOFA) score. SOFA scores were composed of five components: respiratory, 
coagulation, liver, cardiovascular, and renal, and were graded on a scale of 0-4. The higher the 
score the more organ dysfunction was indicated. 
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Table 5.  Inclusion and exclusion criteria for Study 3. 
Inclusion Criteria Exclusion Criteria  
1. Age 18 years or older  1. Age below 18 years 
2. Met the clinical criteria for sepsis within 24 of ICU 
admission (two or more of the following) 
2. Terminal state 
- a core temperature ≥ 38° C o ≤ 36° C 3. Known adverse reaction to albumin administration 
- a heart rate ≥ 90 beats/min 4. Severe sepsis or septic shock in patients after proved 
or suspected head injury, clinically active 
- a respiratory rate ≥ 20 breaths/min or PaCO2 
≤ 32 mmHg or use of mechanical ventilation 
for an acute process 
5. Congestive heart failure (New York Heart Association 
class of 3 or 4) 
- a white blood cell count ≥ 12000/ml or ≤ 
4000/ml or immature neutrophils > 10% 
6. Pathological conditions in which albumin 
administration is clinically indicated (hepatic cirrhosis 
with ascites, intestinal malabsorption syndrome, 
nephrotic syndrome, burns) 
 7. More than 24 hours since inclusion criteria were met 
 8. Religious objection to the administration of human 
blood products 
 9. Inclusion in other experimental studies 
 
 
Study Results 
At 28 days after randomization, 285 of 895 patients in the albumin group and 288 of 900 in the 
crystalloid group had died (relative risk in the albumin group, 1.00; 95% confidence interval [CI], 
0.87 to 1.14; p = 0.94). At 90 days of follow-up, 365 of 888 patients (41.1%) in the albumin 
group and 389 of 893 (43.6%) in the crystalloid group had died (relative risk, 0.94; 95% CI, 0.85 
to 1.05; p = 0.29). A value of less than 0.05 is considered statistically significant. Total daily 
amount of administered fluids in the first 7 days for the albumin group was 3738 ml [interquartile 
range, 3174 to 4437] and in the crystalloid group was 3825 ml [interquartile range, 3205 to 
4533], respectively; p = 0.10).  
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Figure 3. Probability of Survival through 90 days  
 
 
Study Critique  
The trial was funded by the Italian Medicines Agency, which had no role in the conduction of the 
study, the reporting of the data, or the supply of study fluids. This is a strength because there 
was no introduction of bias or push for outcomes as might be seen in a funded study. 
Furthermore, the trial was overseen by the data and safety monitoring board, which is a strength 
because it made sure that trial was conducted within protocol and that the results could be 
extrapolated to the general population once collected. A limitation to this study was that it 
included the use of albumin solutions that were of greater concentration than those used in 
previous studies (20% compared to 4% used in most studies), making it difficult to know if 
percentage of albumin could lead to different outcomes. Furthermore, another limitation to this 
study was that the method in which albumin was administered differed from that of the 
crystalloid solution. In this study albumin was given daily to maintain an albumin level greater 
than 30g per liter whereas, the crystalloid solution was only given when the attending physician 
managing the patient deemed it clinically necessary. In addition, the volume of albumin solution 
that was administered in the study was markedly lower than previous studies due to the fact that 
investigators were not trying to replace intravascular volume. Instead, investigators treatment 
goal was to correct hypoalbuminemia, which could make the comparison of the results to other 
studies difficult. Finally, another limitation to this study was that mortality at 28 days was less 
than what was originally expected, which investigators believe could be linked to the study being 
underpowered. A study that is underpowered is problematic because it increases the risk for 
type 2 error.     
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Discussion  
Shock is a life-threatening complication of severe sepsis that can be corrected with the use of 
aggressive fluid resuscitation in conjunction with empiric antibiotic therapy. Fluid resuscitation is 
aimed at stabilizing the patient by lowering tachycardia, improving blood pressure, normalizing 
depleted electrolytes, and increasing perfusion to vital organs to prevent complications such as 
organ dysfunction and death. The most common method of fluid resuscitation used in ED and 
ICU protocols is the administration of either crystalloid solutions (normal saline, lactated ringers) 
or colloid solutions (hydroxyethyl starch, albumin) to bolster intravascular volume. In our 
research, there was no significant difference in 28-day mortality of shock patients when treated 
with colloid based fluids versus crystalloid based fluids during aggressive resuscitation. The only 
major difference we found, between crystalloid and colloid solutions, was related to total amount 
of fluid administered. For example, in studies 1 and 3, the median amount of total normal saline 
(crystalloid) administered was much larger, as compared to the total amount of albumin (colloid) 
given. However, the total amount of fluid had no significant impact on patient mortality.  
 
Since aggressive fluid resuscitation in the ED and ICU is currently the mainstay of intervention 
in the patient population with sepsis and septic shock, and has been found to be effective, there 
is not much new research being conducted on this topic. Therefore, of the older and smaller 
studies we found, many variables and outcomes were heterogeneous and hard to synthesize, 
making gathering a concise conclusion about the research challenging. Despite the same 
primary endpoint in all studies that were analyzed, there were other variables that were not 
congruent between the trials. Firstly, there were a variety of solutions with different solute 
concentrations and different molecules being used in each of the three studies, which takes 
away from the strength of our review. In addition, the statistical analyses performed in each 
study were not easily comparable because two were analyzed using relative risk of randomized 
control trials and the other looked at odds ratio of a subgroup analysis. Although no study 
outcome was statistically significant, the heterogeneity of the studies as a whole weakens our 
systematic review. 
 
One of the strengths of our review was that all studies we included marked their endpoint for 
assessment of mortality at 28 days. This commonality across all studies was helpful in deciding 
which studies to include in our research. However, we believe this evaluation period was not 
long enough to determine if the use of fluids alone significantly reduced mortality rates. In our 
research, secondary endpoints such as vitals, hemodynamic markers, organ perfusion status 
and other therapeutic intervention data were recorded and analyzed. We feel that these 
endpoints are more clinically relevant and reliable in determining the effectiveness of 
intervention with different fluid solutions rather than mortality, in days, alone. We feel that 
assessing only mortality as the primary endpoint may not properly assess the initial and full 
effect of fluid choice in initial aggressive resuscitation and that other clinically relevant endpoints 
may show one fluid type to be a better choice than another. Furthermore, the method in which 
albumin was administered in study 3 differed significantly from the other two studies. In study 3, 
albumin was given daily to maintain an albumin level greater than 30g per liter whereas, in the 
other studies, albumin was administered via bolus doses in order to resuscitate patients in 
septic shock. This inconsistency in administration and treatment goal, contributed to 
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heterogeneity of our review since patient parameters for daily albumin, compared to bolus 
dosing, might affect clinical outcomes and have skewed the results. A further limitation to this 
research is the acute nature of the condition. For example, in study 3, patients who met criteria 
for the study were subsequently excluded from analysis if they required immediate resuscitation 
prior to ICU admission. By excluding these patients, the investigators might have missed 
important clinical outcomes, which may have altered the results of the study. Finally, a more 
obvious limitation to these studies is size and therefore, power. One of the studies was a 
subgroup analysis which by nature analyzed a smaller population size of a larger randomized 
study. This has potential to weaken our review by introducing type two error. 
 
Table 6. Comparison of Studies Analyzed 
 
Author 
 
Year 
Published 
 
Type of 
Study  
 
Primary 
Outcome 
Fluid(s) analyzed   
P-Value  
Colloid Crystalloid 
Annane et al 2013 RCT 28-day 
mortality  
- Gelatins 
- Dextrans 
- Hydroxyethyl 
starches 
- 4% or 20% Albumin 
- Isotonic Normal Saline 
- Hypotonic Normal 
Saline 
-Lactated Ringer's 
0.26 
Finfer et al  2009 Subgroup 
analysis of 
larger RCT 
28-day 
mortality 
- 4% Albumin  - 0.9% Normal Saline 0.09 
Caironi et al 2014 RCT 28-day 
mortality 
20% Albumin and 0.9 
% Normal Saline  
- 0.9% Normal Saline 
alone 
 
0.94 
 
 
Conclusion  
To date, there is no evidence that a significant benefit exists in choosing crystalloid versus 
colloid for aggressive fluid resuscitation in the acute setting of sepsis and septic shock. 
Knowledge is lacking as to why one type of fluid is not superior to the other in the setting of 
septic shock. Is it the pathophysiology behind sepsis and septic shock that makes fluid 
administration choice inconclusive? Or is it the properties of the specific fluid groups and how 
they work to resuscitate patients during sepsis and septic shock that makes fluid choice 
ambiguous? Despite this gap in knowledge and questions surrounding fluid choice during sepsis 
and shock, there are practical considerations that should be taken into account when choosing 
what fluids to administer. These considerations include total amount used, possible adverse 
outcomes, and cost of fluid solution. These three variables are just as important to a patient's 
overall outcome and represent an area for future research. Other recommendations for future 
research are: primary data with larger sample sizes, role of fluid choice in renal replacement 
therapy in the ICU, and the efficacy in setting specific shock protocols in the ED and ICU in 
order to standardize fluid administration within the study. 
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